CD1D and colitis: As expected, adoptive transfer of MLN-derived CD25+CD4+ T cells from DSS-treated CD1d KO mice into Yeti/CD1d KO recipient mice significantly ameliorated the clinical signs of colitis (i.e., daily body weight loss, disease activity index [DAI], and colon length shortening) compared to the mock-transferred control group (Figure 6B,C).